3104results about "Dragees" patented technology

The compositions and methods provided herein include a pharmaceutical formulation for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical formulations for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof and one or more additional active agents. Also provided herein are methods of treating hair loss by administering to a subject in need thereof a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Further provided herein is a kit including a slow modified release vehicle comprising oral minoxidil or a pharmaceutically acceptable salt thereof.

The invention discloses an oral solid preparation melogabalin besylate tablet containing an excellent stabilizer and a preparation method thereof. A tablet core contains but is not limited to melogabalin besylate, one or two or more filling agents, one or two or more disintegrating agents, one or two or more flow aids and various stabilizer compositions. According to the invention, the optimal stabilizer composition is selected through investigation, so that the growth of main degradation impurities and oxidation impurities is effectively controlled, the product stability is improved, and the tablets with stable quality are obtained. The product is rapidly dissolved out, the dissolution uniformity is good, the intermediate tabletting is smooth, the compressibility is good, and the prepared finished product is good in appearance, free of small holes and stable and controllable in quality.

The invention discloses an amorphous tigorasone solid dispersion which has excellent stability and dissolvability, by adding copovidone, a powerful hydrogen bond is formed between tigorasone and copovidone, and by adjusting the type of an adhesive and the proportion of the adhesive to tigorasone, the problems of easy crystal transformation of amorphous tigorasone, poor solubility and the like are solved. And the technical problem is solved. The tigorazan tablet prepared from the amorphous solid dispersion provided by the invention does not generate crystal transformation after being placed for 30 days under the conditions of 60 DEG C and 75% RH, and the dissolution curve in a standard medium is consistent with that of a reference preparation.

The invention provides a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.

The present invention relates to a stable pharmaceutical composition of therapeutically active agent, wherein the amount of nitrosamine impurity is below the FDA acceptable intake limit for shelf life of the pharmaceutical composition and a process for preparing the same.

The invention provides a melogabalin besylate tablet and a preparation method thereof, the melogabalin besylate tablet comprises a plain tablet and a coating, the plain tablet comprises, by mass, 4.39% of melogabalin besylate, 75-85% of mannitol 150SD, 3-10% of a disintegrating agent, 0.5-3% of a lubricant, 0.1-0.5% of an adsorbent, 1-10% of a filler, 0.5-3% of an antioxidant A and 0.1-3% of an antioxidant B; and the coating comprises the following components in percentage by mass: 30-45% of talcum powder, 2-10% of lauryl sodium sulfate, 30-45% of glycerol monocaprylate / dicaprylate, 2-10% of titanium dioxide, 30-45% of polyvinyl alcohol, 0.5-2% of iron oxide yellow and 0.5-2% of iron oxide red. The melogabalin besylate tablet prepared by the invention uses specific coating composition and specific coating parameters, so that the melogabalin besylate tablet can be stably stored without a drying agent and a composite aluminum bag for medicine packaging, the stability of the tablet is greatly improved, the complexity of equipment required by production is simplified, and the production cost is greatly saved.

Methods for treating immune thrombocytopenia comprising administering at least one compound chosen from (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (PRN1008) and pharmaceutically acceptable salts thereof are disclosed. Pharmaceutical compositions comprising at least one compound chosen from PRN1008 and pharmaceutically acceptable salts thereof are also disclosed.

The invention discloses a melogabalin besylate tablet and a preparation method thereof, a tablet core of the melogabalin besylate tablet comprises melogabalin besylate, a filler, a disintegrating agent, a lubricant and an antioxidant, and the antioxidant comprises sodium ascorbate. Compared with an antioxidant disclosed in the prior art, sodium ascorbate is selected as the antioxidant, so that the content of related substances in the melogabalin besylate preparation can be effectively improved, the growth of main degradation impurities and oxidation impurities is effectively controlled, the stability of the product is improved, and the product is enabled to be quickly dissolved out and good in dissolution uniformity.

The disclosure provides a dosing regimen utilizing an oral extended release formulation for the treatment of treatment-resistant depression and treatment-resistant anxiety.

The invention provides a composition containing dotenorad and a xanthinase inhibitor as well as a preparation method and application of the composition, and belongs to the technical field of pharmacy. The composition provided by the invention comprises dotenorad, a xanthinase inhibitor and at least one pharmaceutically acceptable additive. The composition prepared by the invention has good stability and can be used for clinically treating gout and hyperuricemia.

The invention discloses an atorvaquone enteric-coated tablet, the preparation comprises atorvaquone, glyceryl behenate, teloxpol, a filler, an adhesive, a disintegrating agent and an enteric coating, and the particle size D90 of the atorvaquone is 30-50 [mu] m. The atorvaquone enteric-coated tablet disclosed by the invention is stable and continuous in release and high in bioavailability, can be positioned and released in intestinal tracts and reduce liver circulation, so that the occurrence of phenomena such as liver injury is reduced, the phenomena such as sticking and cracking are avoided in a tabletting process, the quality is qualified and stable, and the dissolution performance and the stability of the atorvaquone enteric-coated tablet are also ensured.

The invention discloses a method for preparing a tigorazan tablet by a fluidized bed granulation method. The method comprises the following steps: 1) preparing a pharmaceutical active component tigorazan and an adhesive into a granulation solution, and granulating the granulation solution and a filler in a fluidized bed to obtain granules; the invention relates to a preparation method of a tigorazan tablet, which comprises the following steps: 1) preparing granules, 2) carrying out dry granulation on the granules, and 3) tabletting the granules obtained after dry granulation in the step 2) and optional pharmaceutically acceptable auxiliary materials so as to obtain the tigorazan tablet. The tablet prepared by a fluidized bed preparation method can solve the problem of easy crystal transformation of amorphous raw materials, and is simple and convenient in process, good in stability and more suitable for commercialized mass production.

The present disclosure provides methods of treating or preventing human immunodeficiency virus (HIV) infection in a patient, comprising orally administering to the patient a therapeutically effective amount of an HIV capsid inhibitor of formula la (e.g. lenacapavir), or a pharmaceutically acceptable salt thereof, according to a specific dosage regimen.

The invention provides a neurosteroid derivative solid dispersion, a preparation method and application thereof, and a medicine containing a hot-melt extrusion solid dispersion, and belongs to the technical field of pharmacy. The preparation method comprises the following steps: carrying out melt extrusion on a raw material mixture at 125-160 DEG C to obtain the neurosteroid derivative solid dispersion, the mixed material comprises an active component, a plasticizer and a carrier material in a mass ratio of 10: (1-15): (10-90); the active component comprises at least one of a neurosteroid derivative (with a structure as shown in a formula 1), an isomer, a solvate and a pharmaceutically acceptable salt thereof; the plasticizer is selected from one or more of polyethylene glycol, poloxamer and Tween, and the average molecular weight of the polyethylene glycol is 1t; 6000, 6000; active components in the neurosteroid derivative solid dispersion exist in an amorphous state. The neurosteroid derivative in the neurosteroid derivative solid dispersion disclosed by the invention has relatively high oral bioavailability. # imgabs0 #

Disclosed herein is a tablet composition comprising 3-[(1S,2S)-1-[5-[(4S)-2,2-dimethyloxolan-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-1-yl]-2-methylcyclopropyl]-4H-1,2,4-oxadiazol-5-one, or a pharmaceutically acceptable salt thereof, and a pH adjuster. In one embodiment, the tablet composition comprises a spray-dried dispersion (SDD) of 3-[(1S,2S)-1-[5-[(4S)-2,2-dimethyloxolan-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-1-yl]-2-methylcyclopropyl]-4H-1,2,4-oxadiazol-5-one, or a pharmaceutically acceptable salt thereof, and the SDD also comprises a polymer for maintaining the amorphous state.

Stable and bioavailable formulations and dosage forms comprising a dispersion (e.g., spray-dried dispersion) of solid amorphous 6-(cyclopropancamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide (Formula (I): BMS-986165) in a solid polymer matrix are provided for the treatment of auto-immune and auto-inflammatory diseases such as an inflammatory bowel disease (IBD) and psoriasis.

The invention relates to the technical field of medicines, in particular to a sustained-release coating as well as a preparation method and application thereof. The coating adopts a three-layer gradient structure design and comprises an inner layer coating, a middle layer coating and an outer layer coating, and the layers are compounded and matched through ethyl cellulose and hydroxypropyl methylcellulose with different molecular weights and are combined with talcum powder filling amount with gradient decreasing and a triethyl citrate plasticizer, so that accurate regulation and control of drug release are realized. Through hierarchical swelling-diffusion dynamic balance, burst release is inhibited, the inner layer has high talcum powder content to resist initial swelling stress, the outer layer has low filling amount to maintain hydrophobic continuity, interface defects are reduced in combination with high-temperature curing, and the release stability and long-term storage performance of drugs such as dihydroergoline mesylate are remarkably improved; the problems of sudden release, damp-heat sensitivity, impurity generation and the like of a traditional single-layer coating are solved.

The invention discloses an abesilil raw material medicine, a composition, a tablet and a preparation method thereof. The particle size distribution of the abesilil raw material medicine is as follows: D10 is more than or equal to 20 microns, D90 is more than or equal to 60 microns and less than or equal to 300 microns, and the span (D90-D10) / D50 is less than or equal to 2.5. According to the present invention, the large raw material particle size within a certain range is provided, the dissolution rate and the dissolution amount of the abelsilil tablet in the pH 6.8 medium can be easily improved, the sticking phenomenon during the tabletting process can be solved, the production process is simple, the production period is short, the production cost is low, the mixing and the tabletting are smooth, and the dissolution end point is high.

The invention relates to a sustained-release tablet capable of avoiding sudden release of a medicine after being taken together with an alcoholic beverage, the sustained-release tablet comprises a sustained-release tablet core and an anti-sudden-release material coating layer wrapping the sustained-release tablet core, and the anti-sudden-release material is composed of a polysaccharide substance and a cellulose derivative, the polysaccharide substance is selected from one or more of guar gum, xanthan gum and Arabic gum, the cellulose derivative is selected from one or more of hydroxypropyl methylcellulose, ethyl cellulose and hydroxyethyl cellulose, and the weight ratio of the polysaccharide substance to the cellulose derivative is 1: 1-10: 1. The sustained-release tablet disclosed by the invention has an excellent burst release resisting effect when being taken together with an alcoholic beverage, and the clinical medication safety and effectiveness of a preparation are improved.

The invention discloses a rod core, a punching type implant as well as a preparation method and application of the punching type implant. The rod core comprises a drug-containing layer, and the drug-containing layer comprises active drugs and auxiliary materials. The auxiliary materials comprise sustained and controlled release auxiliary materials; the molecular weight of the sustained and controlled release auxiliary material is 10000-10000 thousands; the medicine-adjuvant ratio is 1: (0.01-100); the medicine-adjuvant ratio represents the mass ratio of the active medicine to the adjuvant in the medicine-containing layer; optionally, the rod core of the punching type implant also comprises a boosting layer compounded on the medicine-containing layer. The implant provided by the invention can be suitable for most drugs, and can realize long-acting release of the drugs.

The invention discloses a pharmaceutical preparation of a protein kinase inhibitor citrate as well as a preparation method and application of the pharmaceutical preparation. The pharmaceutical preparation comprises citrate of a protein kinase CDK4 / 6 inhibitor and auxiliary materials including a filler, a disintegrating agent, an adhesive, a wetting agent, a glidant and a lubricant. The protein kinase inhibitor citrate pharmaceutical preparation has the advantages of being good in quality, high in stability, high in dissolution rate, simple in preparation method, controllable in quality and the like.

The invention relates to the technical field of pharmaceutical preparations, and discloses a saxagliptin tablet containing a coating layer and a preparation process of the saxagliptin tablet. Comprising the following operation steps: (1) uniformly mixing saxagliptin, a diluent, a disintegrating agent and a lubricant, performing dry granulation, and tabletting to obtain a tablet core; (2) adding hydroxypropyl methyl cellulose phthalate, eudragit and diethyl phthalate into absolute ethyl alcohol, and uniformly mixing to obtain an enteric coating solution; (3) adding modified chitosan and hydroxypropyl methyl cellulose into absolute ethyl alcohol, and uniformly mixing to obtain a gastric-soluble coating solution; step 2: (1) spraying an enteric coating solution on the surface of the tablet core, and drying to form an enteric coating layer; and (2) spraying a gastric-soluble coating solution on the enteric coating layer, and drying to form a gastric-soluble coating layer, thereby obtaining the saxagliptin tablet.

Disclosed herein are compounds, compositions, and methods for promoting neuronal growth and / or improving neuronal structure with the compounds and compositions disclosed herein. Also described are methods of treating diseases or disorders that are mediated by the loss of synaptic connectivity and / or plasticity, such as neurological diseases and disorders, with non-hallucinogenic psychoplastogens.

The doxylamine succinate pyridoxine enteric-coated tablet comprises a tablet core and a coating layer, the coating layer comprises a first isolation layer, an enteric-coated layer and a second isolation layer, the materials of the enteric-coated layer comprise a plasticizer, an anti-sticking agent, a defoaming agent and a flexible coating material, and the flexible coating material accounts for 24-28% of the mass of the tablet core. By adding the flexible coating material, the stability of the pharmaceutical preparation is improved, the difference between batches is reduced, the drug dissolution rate reaches 90% or above, and the pharmaceutical preparation can be quickly released.

The compositions and methods provided herein include a pharmaceutical formulation for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical formulations for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof and one or more additional active agents. Also provided herein are methods of treating hair loss by administering to a subject in need thereof a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Further provided herein is a kit including a slow modified release vehicle comprising oral minoxidil or a pharmaceutically acceptable salt thereof.

The invention provides an extraction method of hirudin, an oral preparation containing the hirudin and a preparation method of the oral preparation, and belongs to the technical field of leech processing and traditional Chinese medicine. The hirudin extraction method comprises the following steps: S1, soaking fresh leeches in a freeze-drying protective agent, taking out the leeches, wiping the surfaces of the leeches, pre-freezing the leeches at the temperature of 40 DEG C below zero to 50 DEG C below zero for 1-2 hours, and freeze-drying the leeches at the temperature of 20 DEG C below zero to 30 DEG C below zero for 4-6 hours to obtain freeze-dried leeches; s2, crushing the freeze-dried leeches, adding the crushed leeches into water, adding enzyme and lecithin, performing enzymolysis for 4-6 hours under the conditions that the temperature is 35-40 DEG C and the pH value is 7.5-8.5, and cooling to room temperature to obtain an enzymolysis product; s3, sterilization, ultrafiltration and drying are conducted, and hirudin is obtained. The hirudin extracted by the method is high in activity and high in recovery rate.

The preparation method comprises the following steps: (1) mixing Chinese herbal medicine powder and a waterproof agent according to a ratio, sieving and uniformly stirring; (2) adding a proper amount of sticky powder and water, mashing into a ball, repeatedly beating and kneading into uniform mud, wrapping with a preservative film, and putting in a shade place for fermenting the mud; (3) kneading the fermented fragrant mud to be round, buckling the fragrant mud into the fragrant bead mold coated with the release agent, compacting, drawing the mold, and scraping off redundant parts; 4) placing the demolded aromatic beads in a dark, dry and ventilated place for drying in the shade, and repeatedly turning over; (5) hollowing out along the axis, and grinding and polishing to prepare the mixed aromatic beads; and 6) baking the polished mixed aromatic beads to prepare the waterproof Chinese herbal medicine mixed aromatic beads. The waterproof agent is added into the synthetic aromatic beads, then the waterproof agent is transferred to the surface through baking, and meanwhile, the interface interaction between the waterproof agent and the synthetic aromatic beads is enhanced, so that the synthetic aromatic beads are tightly wrapped by the waterproof agent, and the waterproof and lasting waterproof effects are achieved.

The invention relates to a pharmaceutical composition comprising benzgalantamine and uses and methods for the preparation thereof. The present invention provides a pharmaceutical composition in the form of a tablet, said tablet comprising a tablet core, wherein said core comprises benzgalantamine (ALPHA-1062) or salt thereof, and an enteric coating, wherein said enteric coating is configured for dissolution at pH 5.5 and above. The pharmaceutical composition could be used in the treatment of a brain disease associated with cognitive impairment and / or with a cholinergic deficit. The invention further provides a method for preparing the pharmaceutical composition.